Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Otsuka Applies for New Indication of Bipolar Disorder for Abilify
February 7, 2011
- Kyowa Kirin Confirms Efficacy of KW-6500 for PD in PIII
February 7, 2011
- Torii Licenses Allergy Immunotherapy Products from ALK
February 7, 2011
- Chugai Seeks Additional Indication for Pegasys
February 7, 2011
- Erbitux plus FOLFOX Prolongs OS: Merck Serono
February 7, 2011
- Januvia Posts Sales of ¥10 Bil. in 2010: MSD
February 7, 2011
- Larger Doses Approved for Acetaminophen in Adults: Showa Yakuhin Kako
February 7, 2011
- The Customer Is KING
February 7, 2011
- Yakult Honsha Aims at Sales of ¥500 Bil. in FY2020
February 7, 2011
- Eisai Applies for Perampanel in the US, Europe
February 7, 2011
- 6-Month Data from PI/II Trial of Collategene Published
February 7, 2011
- Eisai Opens New Company for Cancer Drug Discovery in US
February 7, 2011
- Halaven Receives Positive Opinion from CHMP
February 7, 2011
- Nasivin M Spray Approved as Class 1 OTC Drug
February 7, 2011
- Astellas, Kaketsuken Tie Up to Market Encevac
February 7, 2011
- Gilenya Receives Positive Opinion from CHMP: Novartis
February 7, 2011
- JSMI to Propose Tax Break for All OTC Drugs
February 7, 2011
- AnGes MG to Raise ¥300 Mil. from Shionogi to Develop NF-κB Oligo
February 7, 2011
- GRU to Target Online Sales of OTC Drugs, Basic Dispensing Fees
February 7, 2011
- Shionogi to Recall Class 3 OTC Drugs
February 7, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…